In the latest quarter, 4 analysts provided ratings for Fate Therapeutics (NASDAQ:FATE), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $7.75, along with a high estimate of $10.00 and a low estimate of $7.00. Observing a 72.22% increase, the current average has risen from the previous average price target of $4.50. De…